Results 171 to 180 of about 113,185 (266)

Potential utility of PPARγ agonists in targeting chronic myeloid leukemia stem cells. [PDF]

Ann Hematol
Atef B, El-Ashwah S, Saleh LM, Gawish H, Mabed M.   +4 more
europepmc   +1 more source

Day‐30 IL1RL1, CXCL9 and REG3α are prognostic for survival after mismatched unrelated donor transplantation

British Journal of Haematology, EarlyView.
Summary While plasma‐derived proteins have emerged as potential biomarkers for prognosis after haematopoietic stem cell transplantation (HSCT), there are insufficient data assessing if established proteins interleukin 1 receptor‐like 1 (IL1RL1), chemokine ligand 9 (CXCL9) and regenerating islet‐derived 3‐α (REG3α) retain their utility in the mismatched
Trent Wang, Anna C. Ferreira, Nasheed M. Hossain, Denggang Fu, Elizabeth G. Hill, Antonio M. Jimenez Jimenez, Cara Benjamin, Krishna V. Komanduri, Sophie Paczesny   +8 more
wiley   +1 more source

Review of Bleeding as Initial Presentation in Patients with Chronic Myeloid Leukemia. [PDF]

Clin Appl Thromb Hemost
ALTermanini M, Altrmanini O, Al-Mashdali AF, Ahmed A, Saeed S, Mudarres MF, Saeed M, Abdalla E, Soliman D, Singh K, Saied A, Almahmood M, Suliman A, Qasim H, Abuasab T, Haddad F, Yassin M, Fareed S.   +17 more
europepmc   +1 more source

Transplantation outcomes in patients with Down syndrome‐associated acute lymphoblastic leukaemia: Implications for treatment intensity and the use of novel therapies

British Journal of Haematology, EarlyView.
This nationwide study of 56 patients with Down syndrome‐associated acute lymphoblastic leukaemia (ALL) demonstrated that haematopoietic stem cell transplantation (HSCT) in complete remission (CR)1/2 yields comparable event‐free survival to non‐Down syndrome ALL.
Hisashi Ishida, Yasuhiro Okamoto, Hirotoshi Sakaguchi, Yasuyuki Arai, Tomoaki Ueda, Shunsuke Yamamoto, Mio Yano, Tomoko Yokosuka, Keiko Okada, Maho Sato, Shuhei Karakawa, Ryoji Kobayashi, Keisuke Kato, Katsuyoshi Koh, Toshihiro Fujiki, Kumiko Goi, Shoji Saito, Junko Takita, Takako Miyamura, Yuhki Koga, Nao Yoshida, Atsushi Sato, Moeko Hino, Ken Tabuchi, Yuki Arakawa   +24 more
wiley   +1 more source

Feasibility and Implementation of an eHealth Dashboard for the Remote Monitoring of Dutch Patients With Chronic Myeloid Leukemia: Multimethods Approach. [PDF]

JMIR Cancer
Verweij L, Swillens JEM, Metsemakers SJJPM, Smit Y, Wener E, Ector GICG, Hermens RPMG, Blijlevens NMA.   +7 more
europepmc   +1 more source

Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A nationwide population‐based study

British Journal of Haematology, EarlyView.
Real‐world nationwide data in B‐cell malignancies reveal a markedly increased 1‐year incidence of hospitalized atrial fibrillation with ibrutinib compared with second‐generation Bruton's tyrosine kinase inhibitors and venetoclax, arguing for closer cardiac surveillance.
Yoann Zelmat, Loic Ysebaert, Paul Gautier, Agnes Sommet, Margaux Lafaurie, Fabien Despas   +5 more
wiley   +1 more source

Clinico-Metabolic Profiling Unraveled Key Metabolic Alterations Underlying the Pathophysiology of Chronic Myeloid Leukemia. [PDF]

ACS Omega
Gupta S, Nigam N, Verma SP, Trivedi R, Venkatesh V, Kumar D.   +5 more
europepmc   +1 more source

Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment‐related pathways

British Journal of Haematology, EarlyView.
Selinexor targets molecular pathways critical to myelofibrosis (MF) progenitor cell fitness and demonstrates complementary activity with ruxolitinib, supporting its potential as a novel disease‐modifying therapeutic strategy for MF. Summary Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by splenomegaly, constitutional ...
Trinayan Kashyap, Andrea A. Ellero, Christopher J. Walker, Marie E. Maloof, Min Lu, Lijuan Xia, Ronald Hoffman, Pietro Taverna   +7 more
wiley   +1 more source

Diagnosis and management of neutropenia in adults: Expert guidance

British Journal of Haematology, EarlyView.
Severe neutropenia can result from decreased production of neutrophil precursors in the bone marrow, as in the case of severe congenital neutropenia, or from increased utilization of neutrophils or their accelerated destruction as for drug‐induced neutropenia or autoimmune neutropenia. Severe chronic neutropenia increases susceptibility to bacterial or
Karl Welte, Cornelia Zeidler, Julia Skokowa, Sabine Mellor‐Heineke, Audrey Anna Bolyard, David Dale   +5 more
wiley   +1 more source

Application of NanoString Technologies in Chronic Myeloid Leukemia, Essential Thrombocythemia, Primary Myelofibrosis, and Polycythemia Vera: A Pilot Study. [PDF]

Diagnostics (Basel)
Bae JH, Bae KJ, Cho CH.
europepmc   +1 more source